 -- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports advancing mRNA therapeutics for pulmonary diseases; additional translational research ongoing to optimize future clinical development of mRNA cystic fibrosis programs, including MRT5005 and a next-generation CF candidate -- 